Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade

American Journal of Transplantation

Volumn 14, Issue 9, 2014, Pages 1985-1991

  Gardner, D ^a   Jeffery, L E ^a   Sansom, D M ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Basic (laboratory) research science; costimulation; fusion proteins and monoclonal antibodies: belatacept; fusion proteins and monoclonal antibodies: costimulation molecule specific; immunosuppressant; immunosuppression immune modulation; translational research science

Indexed keywords

ABATACEPT; BELATACEPT; CD28 ANTIGEN; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY CD28; AUTOANTIBODY; LIGAND;

ADAPTIVE IMMUNITY; ANTIGEN FUNCTION; AUTOIMMUNITY; B LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; ENDOCYTOSIS; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TRANSENDOCYTOSIS; TRANSPLANTATION; ANTIBODY PRODUCTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; T LYMPHOCYTE;

ANTIBODY FORMATION; ANTIGENS, CD28; AUTOANTIBODIES; CTLA-4 ANTIGEN; HUMANS; LIGANDS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 84906263734     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12834     Document Type: Review

References (66)

1. Linsley P, Ledbetter J., The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993; 11: 191-212.
2. Sansom DM., CD28, CTLA-4 and their ligands: Who does what and to whom ? Immunology 2000; 101: 169-177.
3. Keir ME, Sharpe AH., The B7/CD28 costimulatory family in autoimmunity. Immunol Rev 2005; 204: 128-143.
4. Sansom DM, Manzotti CN, Zheng Y., What's the difference between CD80 and CD86 ? Trends Immunol 2003; 24: 313-318.
5. Yao S, Zhu Y, Zhu G, et al. B7-h2 is a costimulatory ligand for CD28 in human. Immunity 2011; 34: 729-740.
6. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ., Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27: 111-122.
7. Joffre O, Nolte MA, Sporri R, Reis e Sousa C., Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev 2009; 227: 234-247.
8. Collins A, Brodie D, Gilbert R, et al. The interaction properties of costimulatory molecules revisited. Immunity 2002; 17: 201-210.
9. Lanier L, O'Fallon S, Somoza C, et al. CD80(B7) and CD86(B70) provide similar costimulatory signals for T cell proliferation, cytokine production and generation of CTL. J Immunol 1995; 154: 97-105.
10. Borriello F, Sethna MP, Boyd SD, et al. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity 1997; 6: 303-313.
11. Walker LS., Treg and CTLA-4: Two intertwining pathways to immune tolerance. J Autoimmun 2013; 45: 49-57.
12. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH., Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541-547.
13. Ise W, Kohyama M, Nutsch KM, et al. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol 2010; 11: 129-135.
14. Krummel MF, Allison JP., CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996; 183: 2533-2540.
15. Walunas TL, Bakker CY, Bluestone JA., CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996; 183: 2541-2550.
16. Lee KM, Chuang E, Griffin M, et al. Molecular basis of T cell inactivation by CTLA-4. Science 1998; 282: 2263-2266.
17. Schneider H, Downey J, Smith A, et al. Reversal of the TCR stop signal by CTLA-4. Science 2006; 313: 1972-1975.
18. Stumpf M, Zhou X, Bluestone JA., The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes. J Immunol 2013; 190: 961-969.
19. Araki M, Chung D, Liu S, et al. Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 type 1 diabetes region in nonobese diabetic mice. J Immunol 2009; 183: 5146-5157.
20. Vijayakrishnan L, Slavik JM, Illes Z, et al. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 2004; 20: 563-575.
21. Wing K, Yamaguchi T, Sakaguchi S., Cell-autonomous and non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol 2011; 32: 428-433.
22. Walker LS, Sansom DM., The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011; 11: 852-863.
23. Rudd CE., The reverse stop-signal model for CTLA4 function. Nat Rev Immunol 2008; 8: 153-160.
24. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA., Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev 2011; 241: 180-205.
25. Bachmann MF, Kohler G, Ecabert B, Mak TW, Kopf M., Cutting edge: Lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol 1999; 163: 1128-1131.
26. Homann D, Dummer W, Wolfe T, et al. Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity. J Virol 2006; 80: 270-280.
27. Friedline RH, Brown DS, Nguyen H, et al. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 2009; 206: 421-434.
28. Schmidt EM, Wang CJ, Ryan GA, et al. Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity. J Immunol 2009; 182: 274-282.
29. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322: 271-275.
30. Yamaguchi T, Kishi A, Osaki M, et al. Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression. Proc Natl Acad Sci U S A 2013; 110: E2116-E2125.
31. Tai X, Van Laethem F, Sharpe AH, Singer A., Induction of autoimmune disease in CTLA-4-/- mice depends on a specific CD28 motif that is required for in vivo costimulation. Proc Natl Acad Sci U S A 2007; 104: 13756-13761.
32. Tivol EA, Boyd SD, McKeon S, et al. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J Immunol 1997; 158: 5091-5094.
33. Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4. Science 2011; 332: 600-603.
34. Qureshi O, Kaur S, Hou TZ, et al. Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation. J Biol Chem 2012; 287: 9429-9440.
35. Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S., Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A 2008; 105: 10113-10118.
36. Oderup C, Cederbom L, Makowska A, Cilio CM, Ivars F., Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression. Immunology 2006; 118: 240-249.
37. Kastenmuller W, Gasteiger G, Subramanian N, et al. Regulatory T cells selectively control CD8+ T cell effector pool size via IL-2 restriction. J Immunol 2011; 187: 3186-3197.
38. Riella LV, Sayegh MH., T-cell co-stimulatory blockade in transplantation: Two steps forward one step back. Expert Opin Biol Ther 2013; 13: 1557-1568.
39. Maltzman JS, Turka LA., T-cell costimulatory blockade in organ transplantation. Cold Spring Harb Perspect Med 2013; 3: a015537.
40. Genovese MC, Schiff M, Luggen M, et al. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol 2012; 39: 1546-1554.
41. Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD., A new look at blockade of T-cell costimulation: A therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006; 6: 876-883.
42. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443-453.
43. Vincenti F, Dritselis A, Kirkpatrick P., Belatacept. Nat Rev Drug Discov 2011; 10: 655-656.
44. Wojciechowski D, Vincenti F., Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation. Semin Immunol 2011; 23: 157-164.
45. Tao X, Constant S, Jorritsma P, Bottomly K., Strength of TCR signal determines the costimulatory requirements for Th1 and Th2 CD4+ T cell differentiation. J Immunol 1997; 159: 5956-5963.
46. Gogishvili T, Luhder F, Goebbels S, Beer-Hammer S, Pfeffer K, Hunig T., Cell-intrinsic and -extrinsic control of Treg-cell homeostasis and function revealed by induced CD28 deletion. Eur J Immunol 2013; 43: 188-193.
47. Tai X, Cowan M, Feigenbaum L, Singer A., CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol 2005; 6: 152-162.
48. Zhang R, Huynh A, Whitcher G, Chang J, Maltzman JS, Turka LA., An obligate cell-intrinsic function for CD28 in Tregs. J Clin Invest 2013; 123: 580-593.
49. Gabrysova L, Christensen JR, Wu X, Kissenpfennig A, Malissen B, O'Garra A., Integrated T-cell receptor and costimulatory signals determine TGF-beta-dependent differentiation and maintenance of Foxp3+ regulatory T cells. Eur J Immunol 2011; 41: 1242-1248.
50. Semple K, Nguyen A, Yu Y, Wang H, Anasetti C, Yu XZ., Strong CD28 costimulation suppresses induction of regulatory T cells from naive precursors through Lck signaling. Blood 2011; 117: 3096-3103.
51. Riella LV, Liu T, Yang J, et al. Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. Am J Transplant 2012; 12: 846-855.
52. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
53. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781.
54. Poirier N, Blancho G, Vanhove B., CD28-specific immunomodulating antibodies: What can be learned from experimental models ? Am J Transplant 2012; 12: 1682-1690.
55. Luhder F, Huang Y, Dennehy KM, et al. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med 2003; 197: 955-966.
56. Kitazawa Y, Fujino M, Li XK, et al. Superagonist CD28 antibody preferentially expanded Foxp3-expressing nTreg cells and prevented graft-versus-host diseases. Cell Transplant 2009; 18: 627-637.
57. Kitazawa Y, Fujino M, Sakai T, et al. Foxp3-expressing regulatory T cells expanded with CD28 superagonist antibody can prevent rat cardiac allograft rejection. J Heart Lung Transplant 2008; 27: 362-371.
58. Chen J, Xie L, Toyama S, et al. The effects of Foxp3-expressing regulatory T cells expanded with CD28 superagonist antibody in DSS-induced mice colitis. Int Immunopharmacol 2011; 11: 610-617.
59. Hunig T., The storm has cleared: Lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol 2012; 12: 317-318.
60. Tabares P, Berr S, Romer PS, et al. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08. Eur J Immunol 2014; 44: 1225-1236.
61. Vanhove B, Laflamme G, Coulon F, et al. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood 2003; 102: 564-570.
62. Poirier N, Azimzadeh AM, Zhang T, et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med 2010; 2: 17ra0.
63. Poirier N, Mary C, Dilek N, et al. Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody. Am J Transplant 2012; 12: 2630-2640.
64. Zhang T, Fresnay S, Welty E, et al. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant 2011; 11: 1599-1609.
65. Suchard SJ, Davis PM, Kansal S, et al. A monovalent anti-human CD28 domain antibody antagonist: Preclinical efficacy and safety. J Immunol 2013; 191: 4599-4610.
66. Liu D, Krummey SM, Badell IR, et al. 2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responses. J Exp Med 2014; 211: 297-311.